DuPont’s battle with Nelson Peltz may confound shareholders

Steven Davidoff Solomon writes for The New York Times, May 1, 2015

If there is no deal, shareholders are going to have to face those thorny questions: How do they measure DuPont’s performance — starting from 2007 or 2008? Include the new health and nutrition business or not? The fate of a $60 billion company may hinge on these answers.